Disease Monitoring and Treatment Patterns of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patients with von Hippel-Lindau (VHL) disease experience lifelong tumor risks. This study highlights VHL-associated renal cell carcinoma (VHL-RCC) treatment patterns and monitoring, showing increased healthcare utilization beyond surgery.
Area Of Science
- Oncology
- Genetics
- Nephrology
Background
- Patients with von Hippel-Lindau (VHL) disease face lifelong risks of developing tumors in multiple organs.
- This study focuses on disease monitoring and treatment strategies for VHL-associated renal cell carcinoma (VHL-RCC).
Purpose Of The Study
- To evaluate disease monitoring and treatment patterns in patients with VHL-RCC.
- To compare healthcare utilization between VHL-RCC patients and matched controls.
Main Methods
- Utilized Optum's Clinformatics Data Mart Database (2007-2020) to identify patients with VHL-RCC.
- Matched VHL-RCC patients with controls without VHL or RCC.
- Analyzed treatment patterns, pain management drug use, disease monitoring, and specialist visits using generalized linear models.
Main Results
- The most common VHL-RCC treatments were nephrectomy and targeted therapies.
- VHL-RCC patients exhibited higher pain management drug use and received more disease monitoring procedures and specialist visits compared to controls.
- Median time to first RCC tumor treatment was 48 days from diagnosis.
Conclusions
- The management of VHL-RCC involves extensive treatments beyond surgical interventions.
- Effective tumor control strategies are crucial for mitigating the morbidity associated with VHL-RCC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
